French-American alliance for diabetes drugs
Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S. and Japan agreement for the discovery and development of novel TGR5 agonists for the treatment of type 2 diabetes and other metabolic indications. The collaboration will leverage Intercept's drug discovery platform based on its proprietary bile acid analogue chemistry and expertise targeting TGR5 and other bile receptors. Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism.
Under the terms of the agreement, Intercept will receive up to $163 million in total upfront, plus research support and milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Intercept and Servier will jointly support the discovery effort, while Servier alone will be responsible for all costs associated with the global development, regulatory approval and commercialisation of any compound selected as a lead candidate by the parties. Intercept retains all rights in the U.S. and Japan.